Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia

[1]  J. Kim,et al.  Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. , 2001, Human gene therapy.

[2]  J. Y. Scheerlinck,et al.  Genetic adjuvants for DNA vaccines. , 2001, Vaccine.

[3]  S. Hoffman,et al.  Improving Protective Immunity Induced by DNA-Based Immunization: Priming with Antigen and GM-CSF-Encoding Plasmid DNA and Boosting with Antigen-Expressing Recombinant Poxvirus1 2 , 2000, The Journal of Immunology.

[4]  Craig W. Reynolds,et al.  Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.

[5]  S. Rosenberg,et al.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. , 1997, Journal of the National Cancer Institute.

[6]  S. Levy,et al.  Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. , 1997, Blood.

[7]  J. Ulmer,et al.  Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization , 1997, Journal of virology.

[8]  N. Restifo.  The new vaccines: building viruses that elicit antitumor immunity. , 1996, Current opinion in immunology.

[9]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[10]  P. Cresswell,et al.  Processing and delivery of peptides presented by MHC class I molecules. , 1996, Current opinion in immunology.

[11]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[12]  A. Lanzavecchia.  How can cryptic epitopes trigger autoimmunity? , 1995, The Journal of experimental medicine.

[13]  Z. Xiang,et al.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. , 1995, Immunity.

[14]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Pardoll.  New strategies for enhancing the immunogenicity of tumors. , 1993, Current opinion in immunology.

[16]  P. Martiat,et al.  Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. , 1993, Blood.

[17]  Bin Wang,et al.  Gene inoculation generates immune responses against human immunodeficiency virus type 1. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Levy,et al.  Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma , 1993, Nature.

[19]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[20]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[21]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[22]  S. Altmann,et al.  Single proline substitutions in predicted alpha-helices of murine granulocyte-macrophage colony-stimulating factor result in a loss in bioactivity and altered glycosylation. , 1991, The Journal of biological chemistry.

[23]  J. Pierce,et al.  Induction of the granulocyte-macrophage colony-stimulating factor (CSF) receptor by granulocyte CSF increases the differentiative options of a murine hematopoietic progenitor cell , 1990, Molecular and cellular biology.

[24]  M. Perkus,et al.  Cloning and expression of foreign genes in vaccinia virus, using a host range selection system , 1989, Journal of virology.

[25]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[26]  R. Lathe,et al.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Moss,et al.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes , 1984, Journal of virology.

[28]  P. Ralph,et al.  Murine B cell leukemia line with inducible surface immunoglobulin expression. , 1978, Journal of immunology.

[29]  R. Parkhouse,et al.  Characterization of murine colony-forming B cells. I. Distribution, resistance to anti-immunoglobulin antibodies, and expression of Ia antigens. , 1978, Journal of immunology.

[30]  H. Deng,et al.  Genetic vaccines — a revolution in vaccinology? , 2004, Springer Seminars in Immunopathology.

[31]  G. Haas,et al.  Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells. , 2001, Journal of immunotherapy.

[32]  P. Musiani,et al.  Cytokines, tumour-cell death and immunogenicity: a question of choice. , 1997, Immunology today.

[33]  A. Miller,et al.  Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.